Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593876 | 0.69 | SLC6A4 (0.50) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 | |
| SCHEMBL7806789 | 0.65 | SLC6A3 (0.44) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 | |
| SCHEMBL14625009 | 0.65 | SLC6A4 (0.55) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 | |
| SCHEMBL14625431 | 0.64 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL19767370 | 0.63 | SLC6A4 (0.57) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 | |
| SCHEMBL5196186 | 0.62 | SLC6A2 (0.57) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 | |
| SCHEMBL10993988 | 0.61 | SLC6A4 (0.84) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 | |
| SCHEMBL7003057 | 0.60 | SLC6A3 (0.41) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 | |
| SCHEMBL2473828 | 0.59 | SLC6A4 (1.00) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 | |
| SCHEMBL13272946 | 0.59 | SLC6A4 (1.00) | SLC6A4SLC6A3CYP2D6SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149095-B1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH AS (DK) | 2004-01-21 | — | — | EP | disclosed |
| US-6617459-B2 | 8-azabicyclo(3.2.1)oct-2-ene and 9-azabicyclo(3.3.1)non-2-ene derivatives; monoamine neurotransmitter and serotonine reuptake inhibitors; radionuclide-labeled derivatives for diagnosis and detection | NEUROSEARCH A/S (DK) | 2003-09-09 | — | — | US | disclosed |
| US-20010047028-A1 | Novel azabicyclo derivatives and their use | ANIONA APS (DK) | 2001-11-29 | — | — | US | disclosed |
| EP-1149095-A1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2001-10-31 | — | — | EP | disclosed |
| EP-1068204-A1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND USE OF 8-AZABICYCLO 3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND UNLABELLED FORM | NEUROSEARCH A/S (DK) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000044746-A1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2000-08-03 | — | — | WO | disclosed |
| WO-1999038866-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED FORM AND USE OF 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND UNLABELLED FORM | NEUROSEARCH A/S (DK) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047028-A1 | Novel azabicyclo derivatives and their use | TACR2, TACR3, GPR68 | SLC6A4 519/4885SLC6A3 233/4885CYP2D6 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.